NASDAQ:IMGN

ImmunoGen Stock Forecast, Price & News

$6.68
-0.09 (-1.33 %)
(As of 06/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.66
$6.89
50-Day Range
$5.79
$8.14
52-Week Range
$3.38
$10.88
Volume1.27 million shs
Average Volume2.29 million shs
Market Capitalization$1.34 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.36
30 days | 90 days | 365 days | Advanced Chart
Receive IMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter.


ImmunoGen logo

About ImmunoGen

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with Roche; Amgen/Oxford BioTherapeutics; sanofi-aventis U. S. LLC; Biotest AG; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Fusion Pharmaceuticals Inc.; Debiopharm International SA; Jazz Pharmaceuticals Ireland Limited; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.47 out of 5 stars

Medical Sector

628th out of 2,100 stocks

Pharmaceutical Preparations Industry

305th out of 831 stocks

Analyst Opinion: 3.3Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











ImmunoGen (NASDAQ:IMGN) Frequently Asked Questions

Is ImmunoGen a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ImmunoGen stock.
View analyst ratings for ImmunoGen
or view top-rated stocks.

What stocks does MarketBeat like better than ImmunoGen?

Wall Street analysts have given ImmunoGen a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ImmunoGen wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is ImmunoGen's next earnings date?

ImmunoGen is scheduled to release its next quarterly earnings announcement on Friday, July 30th 2021.
View our earnings forecast for ImmunoGen
.

How were ImmunoGen's earnings last quarter?

ImmunoGen, Inc. (NASDAQ:IMGN) issued its earnings results on Monday, May, 10th. The biotechnology company reported ($0.17) EPS for the quarter, topping the Zacks' consensus estimate of ($0.19) by $0.02. The biotechnology company earned $15.70 million during the quarter, compared to analysts' expectations of $17.52 million. ImmunoGen had a negative trailing twelve-month return on equity of 169.72% and a negative net margin of 36.62%. ImmunoGen's quarterly revenue was up 18.0% compared to the same quarter last year.
View ImmunoGen's earnings history
.

How has ImmunoGen's stock price been impacted by Coronavirus?

ImmunoGen's stock was trading at $3.37 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IMGN stock has increased by 98.2% and is now trading at $6.68.
View which stocks have been most impacted by COVID-19
.

What guidance has ImmunoGen issued on next quarter's earnings?

ImmunoGen issued an update on its FY 2021 earnings guidance on Tuesday, June, 8th. The company provided earnings per share guidance of $- for the period. The company issued revenue guidance of $65 million-75 million, compared to the consensus revenue estimate of $70.02 million.

What price target have analysts set for IMGN?

7 Wall Street analysts have issued 12-month price targets for ImmunoGen's stock. Their forecasts range from $6.00 to $14.00. On average, they expect ImmunoGen's stock price to reach $10.10 in the next year. This suggests a possible upside of 51.2% from the stock's current price.
View analysts' price targets for ImmunoGen
or view top-rated stocks among Wall Street analysts.

Who are ImmunoGen's key executives?

ImmunoGen's management team includes the following people:
  • Mr. Mark J. Enyedy, Pres, CEO & Director (Age 57, Pay $1.2M)
  • Dr. Thomas Ryll, Sr. VP of Technical Operations (Age 60, Pay $526.23k)
  • Dr. Anna Berkenblit, Sr. VP & Chief Medical Officer (Age 51, Pay $602.68k)
  • Ms. Susan Altschuller Ph.D., Sr. VP & CFO (Age 39)
  • Ms. Renee Lentini, VP of Fin., Principal Accounting Officer & Corp. Controller (Age 43)
  • Ms. Courtney O'Konek, Sr. Director of Corp. Communications & Investor Relations
  • Ms. Audrey Bergan, VP & Chief HR Officer
  • Dr. Theresa G. Wingrove, Sr. VP of Regulatory Affairs & Quality (Age 63)
  • Ms. Stacy A. Coen, Sr. VP & Chief Bus. Officer (Age 50)
  • Mr. Joseph J. Kenny, Sec.

What is Mark J. Enyedy's approval rating as ImmunoGen's CEO?

16 employees have rated ImmunoGen CEO Mark J. Enyedy on Glassdoor.com. Mark J. Enyedy has an approval rating of 64% among ImmunoGen's employees.

Who are some of ImmunoGen's key competitors?

What other stocks do shareholders of ImmunoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Immunomedics (IMMU), Advanced Micro Devices (AMD), AbbVie (ABBV), Gilead Sciences (GILD), OPKO Health (OPK), AT&T (T) and Dynavax Technologies (DVAX).

What is ImmunoGen's stock symbol?

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

Who are ImmunoGen's major shareholders?

ImmunoGen's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.16%), Redmile Group LLC (4.85%), Orbimed Advisors LLC (4.57%), Clearbridge Investments LLC (3.06%), Ameriprise Financial Inc. (2.80%) and Morgan Stanley (2.10%). Company insiders that own ImmunoGen stock include Craig Barrows, David G Foster, Mark J Enyedy and Thomas Ryll.
View institutional ownership trends for ImmunoGen
.

Which major investors are selling ImmunoGen stock?

IMGN stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Redmile Group LLC, Clearbridge Investments LLC, Morgan Stanley, Cubist Systematic Strategies LLC, Credit Suisse AG, Allianz Asset Management GmbH, and Panagora Asset Management Inc..
View insider buying and selling activity for ImmunoGen
or view top insider-selling stocks.

Which major investors are buying ImmunoGen stock?

IMGN stock was purchased by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Ameriprise Financial Inc., Compagnie Lombard Odier SCmA, BlackRock Inc., D. E. Shaw & Co. Inc., Federated Hermes Inc., Geode Capital Management LLC, and Citigroup Inc..
View insider buying and selling activity for ImmunoGen
or or view top insider-buying stocks.

How do I buy shares of ImmunoGen?

Shares of IMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ImmunoGen's stock price today?

One share of IMGN stock can currently be purchased for approximately $6.68.

How much money does ImmunoGen make?

ImmunoGen has a market capitalization of $1.34 billion and generates $132.30 million in revenue each year. The biotechnology company earns $-44,370,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis.

How many employees does ImmunoGen have?

ImmunoGen employs 79 workers across the globe.

What is ImmunoGen's official website?

The official website for ImmunoGen is www.immunogen.com.

Where are ImmunoGen's headquarters?

ImmunoGen is headquartered at 830 WINTER ST, WALTHAM MA, 02451.

How can I contact ImmunoGen?

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-895-0600 or via email at [email protected]


This page was last updated on 6/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.